Patents by Inventor Iris Ziegler
Iris Ziegler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11007156Abstract: A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt. % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.Type: GrantFiled: October 14, 2019Date of Patent: May 18, 2021Assignee: GRUENENTHAL GMBHInventors: Johannes Bartholomaeus, Iris Ziegler
-
Publication number: 20200038344Abstract: A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt. % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.Type: ApplicationFiled: October 14, 2019Publication date: February 6, 2020Applicant: GRUENENTHAL GMBHInventors: Johannes BARTHOLOMAEUS, Iris ZIEGLER
-
Publication number: 20180221308Abstract: A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.Type: ApplicationFiled: April 2, 2018Publication date: August 9, 2018Inventors: Johannes BARTHOLOMAEUS, Iris ZIEGLER
-
Patent number: 9750701Abstract: The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a breaking strength B2 of less than 500 N in direction of extension E2.Type: GrantFiled: December 11, 2015Date of Patent: September 5, 2017Assignee: GRÜNENTHAL GMBHInventors: Eugeen Marie Jozef Jans, Filip René Irena Kiekens, Jody Firmin Marceline Voorspoels, Anne Faure, Iris Ziegler, Elisabeth Arkenau-Maric, Lutz Barnscheid, Johannes Bartholomäus, Marc Frevel, Eric Galia, Andrea Schüessele
-
Publication number: 20170087103Abstract: A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.Type: ApplicationFiled: December 13, 2016Publication date: March 30, 2017Inventors: JOHANNES BARTHOLOMAEUS, IRIS ZIEGLER
-
Publication number: 20160199305Abstract: The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a breaking strength B2 of less than 500 N in direction of extension E2.Type: ApplicationFiled: December 11, 2015Publication date: July 14, 2016Applicant: GRÜNENTHAL GMBHInventors: EUGEEN MARIE JOZEF JANS, FILIP RENÉ IRENA KIEKENS, JODY FIRMIN MARCELINE VOORSPOELS, ANNE FAURE, IRIS ZIEGLER, ELISABETH ARKENAU-MARIC, LUTZ BARNSCHEID, JOHANNES BARTHOLOMÄUS, MARC FREVEL, ERIC GALIA, ANDREA SCHÜESSELE
-
Publication number: 20160151309Abstract: A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.Type: ApplicationFiled: February 8, 2016Publication date: June 2, 2016Inventors: Johannes BARTHOLOMAEUS, Iris Ziegler
-
Publication number: 20140322323Abstract: The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a breaking strength B2 of less than 500 N in direction of extension E2.Type: ApplicationFiled: April 25, 2014Publication date: October 30, 2014Applicant: GRÜNENTHAL GMBHInventors: EUGEEN MARIE JOZEF JANS, FILIP RENÉ IRENA KIEKENS, JODY FIRMIN MARCELINE VOORSPOELS, ANNE FAURE, IRIS ZIEGLER, ELISABETH ARKENAU-MARIC, LUTZ BARNSCHEID, JOHANNES BARTHOLOMÄUS, MARC FREVEL, ERIC GALIA, ANDREA SCHÜESSELE
-
Patent number: 8747900Abstract: The invention relates to a pharmaceutical composition comprising cefuroximaxetil and at least one carrageenan selected from the group consisting of ?-carrageenan, ?-carrageenan and -carrageenan. The invention furthermore relates to pellets, to a multiparticulate, pharmaceutical dosage form and to a novel crystalline modification of cefuroximaxetil.Type: GrantFiled: April 25, 2006Date of Patent: June 10, 2014Assignee: Gruenenthal GmbHInventors: Iris Ziegler, Andreas Fischer
-
Patent number: 8722086Abstract: A multiparticulate dosage form formulated to make misuse more difficult containing least one active substance with potential for misuse (A), at least one synthetic or natural polymer (C), optionally at least one natural, semi-synthetic or synthetic wax (D), at least one disintegrant (E) and optionally one or more additional physiologically compatible excipients (B), wherein the individual particles of the dosage form display a breaking strength of at least 500 N and a release of active substance of at least 75% after 45 minutes measured according to Ph.Eur. in the paddle mixer with sinker in 600 ml of aqueous buffer solution with a pH value of 1.2 at 37° C. and 75 rpm.Type: GrantFiled: March 7, 2008Date of Patent: May 13, 2014Assignee: Gruenenthal GmbHInventors: Elisabeth Arkenau-Marić, Johannes Bartholomaeus, Iris Ziegler, Marcel Haupts
-
Publication number: 20130251759Abstract: The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a breaking strength B2 of less than 500 N in direction of extension E2.Type: ApplicationFiled: January 16, 2013Publication date: September 26, 2013Applicant: GRUENENTHAL GMBHInventors: EUGEEN MARIE JOZEF JANS, FILIP RENÉ IRENA KIEKENS, JODY FIRMIN MARCELINE VOORSPOELS, ANNE FAURE, IRIS ZIEGLER, ELISABETH ARKENAU-MARIC, LUTZ BARNSCHEID, JOHANNES BARTHOLOMUÄS, MARC FREVEL, ERIC GALIA, ANDREA SCHÜESSELE
-
Publication number: 20130237608Abstract: A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt. % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.Type: ApplicationFiled: April 23, 2013Publication date: September 12, 2013Applicant: GRUENENTHAL GmbHInventors: Johannes BARTHOLOMAEUS, Iris ZIEGLER
-
Patent number: 8383152Abstract: The invention relates to a pharmaceutical dosage form, preferably with controlled release of a pharmacologically active compound (A) contained therein, the pharmaceutical dosage form very preferably being tamper-resistant and most preferably having a breaking strength B1 of at least 500 N in direction of extension E1 and having a breaking strength B2 of less than 500 N in direction of extension E2.Type: GrantFiled: January 23, 2009Date of Patent: February 26, 2013Assignee: Gruenenthal GmbHInventors: Eugeen Marie Jozef Jans, Filip René Irena Kiekens, Jody Firmin Marceline Voorspoels, Anne Faure, Elisabeth Arkenau-Maric, Lutz Barnscheid, Johannes Bartholomäus, Marc Frevel, Eric Galia, Iris Ziegler, Andrea Schüssele
-
Patent number: 8361506Abstract: A multiparticulate, pharmaceutical dosage form containing at least one antibiotic which is sparingly wettable with aqueous media or sparingly soluble in aqueous media and a combination of carrageenan and tricalcium phosphate and optionally sucrose ester. Also, an administration system having this dosage form arranged in a drinking straw with at least one barrier device for single administration, optionally together with a conveying liquid.Type: GrantFiled: June 22, 2007Date of Patent: January 29, 2013Assignee: Gruenenthal GmbHInventors: Iris Ziegler, Johannes Bartholomäus, Jessica Redmer
-
Patent number: 8173164Abstract: An oral administration unit containing the active substances Tramadol and Diclofenac and/or physiologically acceptable salts thereof, in which both active substances are contained in the same administration unit as two separately formulated subunits.Type: GrantFiled: September 22, 2003Date of Patent: May 8, 2012Assignee: Gruenenthal GmbHInventors: Johannes Bartholomaeus, Iris Ziegler
-
Patent number: 8147874Abstract: Coated pellets which comprise an active pharmaceutical ingredient that is poorly soluble in water, release at least 80% of the active ingredient under in vitro conditions in phosphate buffer at pH 5.0 after 30 minutes and are bioequivalent to a liquid formulation of the active ingredient under in vitro fed status test conditions and/or are coated with a composition, which includes a lipophilic component (A) and a hydrogel former (B), wherein the pure lipophilic component (A) has (i) an HLB value of ?5, and/or (ii) a melting range of ?60° C., and/or (iii) a solidification range ? of less than 35° C., and/or (iv) a density of ?0.80 g cm?3.Type: GrantFiled: June 12, 2009Date of Patent: April 3, 2012Assignee: Gruenenthal GmbHInventors: Iris Ziegler, Irwin Jacobs
-
Publication number: 20120034304Abstract: A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt. % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.Type: ApplicationFiled: September 23, 2011Publication date: February 9, 2012Applicant: GRUENENTHAL GmbHInventors: Johannes BARTHOLOMAEUS, Iris Ziegler
-
Patent number: 7906141Abstract: A sustained-release, oral pharmaceutical formulation of tramadol comprising a compound formed in situ of tramadol or its salt and a pharmaceutically acceptable acidic substance. The compound formed in situ has a desired water solubility. Also provided are methods of treatment using the pharmaceutical formulations. Method for preparing such formulations are also provided. The preparation method comprises repeatedly mixing tramadol or its salt with the acidic substance, and moistening the mixture and formulating the mixture under an energy input, such as heat or pressure. Optionally, drying, repeated granulating, extrudation and pelleting may also be included.Type: GrantFiled: February 28, 2002Date of Patent: March 15, 2011Assignee: Gruenenthal GmbHInventors: Iris Ziegler, Johannes Bartholomaeus
-
Patent number: 7897173Abstract: A sustained-release, oral pharmaceutical formulation of tramadol comprising a compound formed in situ of tramadol or a tramadol salt and a pharmaceutically acceptable acidic substance. The compound formed in situ has a desired water solubility. Also provided are methods of treatment using the pharmaceutical formulations. Method for preparing such formulations are also provided. The preparation method comprises repeatedly mixing tramadol or its salt with the acidic substance, and moistening the mixture and formulating the mixture under an energy input, such as heat or pressure. Optionally, drying, repeated granulating, extrudation and pelleting may also be included.Type: GrantFiled: May 4, 2004Date of Patent: March 1, 2011Assignee: Gruenenthal GmbHInventors: Iris Ziegler, Johannes Bartholomaeus
-
Publication number: 20100068290Abstract: Coated pellets which comprise an active pharmaceutical ingredient that is poorly soluble in water, release at least 80% of the active ingredient under in vitro conditions in phosphate buffer at pH 5.0 after 30 minutes and are bioequivalent to a liquid formulation of the active ingredient under in vitro fed status test conditions and/or are coated with a composition, which includes a lipophilic component (A) and a hydrogel former (B), wherein the pure lipophilic component (A) has (i) an HLB value of ?5, and/or (ii) a melting range of ?60° C, and/or (iii) a solidification range ? of less than 35° C., and/or (iv) a density of ?0.80 g cm?3.Type: ApplicationFiled: June 12, 2009Publication date: March 18, 2010Applicant: Gruenenthal GmbHInventors: Iris Ziegler, Irwin Jacobs